Peripheral blood CD26+ leukaemia stem cell monitoring in CML during TKI treatment

• Date : 2020-12-08
• 1    
  0

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL

• Date : 2020-12-08
• 0    
  0

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA

• Date : 2020-12-08
• 0    
  0

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph+ ALL

• Date : 2020-12-08
• 0    
  0

Off-the-shelf multi-virus specific T cells following haematopoietic stem cell transplantation

• Date : 2020-12-08
• 0    
  0

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy

• Date : 2020-12-08
• 0    
  0

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk

• Date : 2020-12-08
• 0    
  0

Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML

• Date : 2020-12-08
• 0    
  0

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

• Date : 2020-12-08
• 0    
  0

Treating acute leukaemias of ambiguous lineage

• Date : 2020-12-08
• 0    
  0

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia

• Date : 2020-12-08
• 0    
  0

ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia

• Date : 2020-12-08
• 0    
  0

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed

• Date : 2020-12-08
• 0    
  0

PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell

• Date : 2020-12-08
• 0    
  0

MURANO trial: Sustained disease survival in CLL following venetoclax plus rituximab

• Date : 2020-12-08
• 0    
  0

Researchers trace the origin of blood cancer to early childhood, decades before diagnosis

• Date : 2020-12-08
• 0    
  0

ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosphoethanolamine

• Date : 2020-12-08
• 0    
  0

The Burkitt lymphoma international prognostic index

• Date : 2020-12-08
• 0    
  0

Real-world evidence of the use of carfilzomib among multiple myeloma patients

• Date : 2020-12-08
• 0    
  0

A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and Bortezomib

• Date : 2020-12-08
• 0    
  0

Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients

• Date : 2020-12-08
• 0    
  0

Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute

• Date : 2020-12-08
• 0    
  0

Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients

• Date : 2020-12-08
• 0    
  0

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves

• Date : 2020-12-08
• 0    
  0

Clinical activity and safety of cevostamab in relapsed/refractory multiple myelomavvvv

• Date : 2020-12-08
• 0    
  0

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma

• Date : 2020-12-08
• 0    
  0

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the random

• Date : 2020-12-08
• 0    
  0

Latest advice on the management of multiple myeloma patients

• Date : 2020-12-08
• 0    
  0

ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

• Date : 2020-12-08
• 0    
  0

ASH 2020: Targeted therapies in r/r multiple myeloma

• Date : 2020-12-08
• 0    
  0

E2E Chen Kumar-ecancer Web

• Date : 2020-12-08
• 0    
  0

FORTE Trial: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma

• Date : 2020-12-08
• 0    
  0

B-HOLISTIC study and the importance of r/r Hodgkin lymphoma real world evidence data

• Date : 2020-12-08
• 0    
  0

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated

• Date : 2020-12-08
• 0    
  0

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

• Date : 2020-12-08
• 0    
  0

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

• Date : 2020-12-08
• 0    
  0

Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukaemia

• Date : 2020-12-08
• 0    
  0

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

• Date : 2020-12-08
• 0    
  0

Predictive factors for overall survival in chronic myeloid leukaemia patients

• Date : 2020-12-08
• 0    
  0

Bosutinib versus imatinib for newly diagnosed chronic phase CML: Bfore trial final 5-year results

• Date : 2020-12-08
• 0    
  0

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients

• Date : 2020-12-08
• 0    
  0

Five year update of ECHELON-1 for classical Hodgkin lymphoma

• Date : 2020-12-08
• 0    
  0

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated

• Date : 2020-12-08
• 0    
  0

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory

• Date : 2020-12-08
• 0    
  0

Blinatumomab and oral TKIs for the treatment of Ph+ ALL

• Date : 2020-12-08
• 0    
  0

Congrès ParkourS 2025

• Date : 2025-01-30
• 424    
  0

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

• Date : 2023-06-30
• 3582    
  6

International Society on Thrombosis and Haemostasis congress - ISTH 2023

• Date : 2023-06-24
• 5132    
  0

The European Hematology Association - EHA 2023

• Date : 2023-06-08
• 8350    
  0

MDS - 17th International Congress on Myelodysplastic Syndromes

• Date : 2023-05-03
• 12876    
  0